Search our science

Kjalke, M., Kjelgaard-Hansen, M., Andersen, S. and Hilden, I. (2021), Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses. J Thromb Haemost. https://doi.org/10.1111/jth.15323

Shapiro A, Castaman G, Cepo K, Tønder SM, Matsushita T, Poulsen LH, Young G, Zupancic-Šalek S, Jiménez Yuste V. Safety and Longer-term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Haemophilia. 2021;27(S2): 128. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236

Shapiro A, Castaman G, Cepo K, Tønder SM, Matsushita T, Poulsen LH, Young G, Zupancic-Šalek S, Jiménez Yuste V. Safety and Longer-term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia A or B with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Haemophilia. 2021;27(S2): 128. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236

(2021), Abstract. Haemophilia, 27: 18-181. https://doi.org/10.1111/hae.14236

Augustsson C, Ridell A, Fernandez-Bello I, Butta N, Kjalke M, Astermark J, Eichler H, Jimenez Yuste V, Chowdary P. ROTEM assay conditions sensitive to concizumab . Haemophilia. 2021;27(S2): https://doi.org/10.1111/hae.14236

Seremetis S, Cepo K, Rasmussen JS, Rose TH, Søren Tamer, Porstmann T, Haaning J. Risk Mitigation Strategy for Concizumab Clinical Trials after Pause Due to Non-fatal Thrombotic Events . Haemophilia. 2021;27(S2): 124. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236

Augustsson C, Ridell A, Fernandez-Bello I, Butta N, Kjalke M, Astermark J, Eichler H, Jimenez Yuste V, Chowdary P. ROTEM assay conditions sensitive to concizumab . Haemophilia. 2021;27(S2): https://doi.org/10.1111/hae.14236

Eichler H, Angchaisuksiri P, Astermark J, Benson G, Cepo K, Chowdary P, Hansen T, Kavakli K, Wheeler AP, Oldenburg J. Safety and longer-term efficacy of concizumab prophylaxis in patients with severe haemophilia A without inhibitors: Results from the extension part of the phase 2 explorer5 Trial . Haemophilia. 2021;27(S2): 95. https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14236

Witkop M, Wang M, Hernandez G, Recht M, Baumann K, Cooper DL. Impact of haemophilia on patients with mild-to-moderate disease: results from the P-FiQ and B-HERO-S studies . Haemophilia. 2021;27(Suppl. 1): 8-16. doi:https://doi.org/10.1111/hae.14251 https://onlinelibrary.wiley.com/doi/10.1111/hae.14251

Walsh C, Boggio L, Brown-Jones L, Miller R, Hawk S, Savage B, Hansen K, Molter D, Baumann K, Dunn S, Skinner M, Haugstad K, Johnson S, Davenport T, Bradbury M, Witkop M, Saad H, Cooper DL. Identified unmet needs and proposed solutions in mild-to-moderate haemophilia: a summary of opinions from a roundtable of haemophilia experts. Haemophilia. 2021;27(Suppl. 1): 25-32. doi:https://doi.org/10.1111/hae.14168 https://onlinelibrary.wiley.com/doi/10.1111/hae.14168

Rajpurkar M, Forsyth A, Manco-Johnson M. Current challenges for men and women with mild-to-moderate haemophilia. Haemophilia. 2021;27(Suppl. 1): 5-7. doi:https://doi.org/10.1111/hae.14193 https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.14193

Napolitano M, Olsen AA, Nøhr AM, Eichler H. Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C. J Blood Med. 2021;12:9-20

https://doi.org/10.2147/JBM.S284060

Benson G, Morton T, Thomas H, Lee XY . Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective. Clinicoecon Outcomes Res. 2021;13: 39-51. doi:https://doi.org/10.2147/CEOR.S280574